PALB2 and breast carcinoma: Female breast cancer patients who carried one of the two Polish PALB2 founder mutations had a 10-year survival of 48%, compared to 75% for patients with breast cancer without a PALB2 mutation (HR = 2.27, 95% CI 1.64–3.15; p < 0.0001).